Market Overview

PAREXEL, National Taiwan University Hospital Enter Research Partnership in Taiwan


PAREXEL International Corporation (NASDAQ: PRXL) and the National Taiwan University Hospital (NTUH) announced today that they have established an alliance. Under the agreement, PAREXEL and NTUH will collaborate to provide drug development services in Taiwan.

"Partnering with National Taiwan University Hospital further enhances our ability to meet the increasing demand from our clients to provide a full scope of Phase I-IV clinical trials in a rapidly growing market," said Joe Avellone, M.D., Corporate Senior Vice President, Clinical Research Services, PAREXEL International. "The National Taiwan University Hospital is well-known and highly respected in Taiwan. We are pleased to have the opportunity to work together to advance our biopharmaceutical clients' programs in the region and help them to compete more effectively in the global marketplace."

"We are delighted to collaborate with PAREXEL, a world-leading biopharmaceutical services provider" said Ming-Fong Chen, M.D., Ph.D., Superintendent at National Taiwan University Hospital. "PAREXEL has a wealth of experience in both local and global clinical development programs. This partnership will bring opportunities for both PAREXEL and NTUH to leverage our combined expertise in order to accelerate clinical development programs in Taiwan and meet patients' need

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (PRXL)

View Comments and Join the Discussion!

Monroe Capital Corporation Closed on Over-Allotment Option by Underwriters Relating to IPO

Ceragon Receives Major Wireless Network Deals Totaling $28M